{"id":"receipt-of-enoxaparin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Bleeding"},{"rate":"0.1-1","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Injection site hematoma"},{"rate":"1-3","effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL1201476","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. It is administered subcutaneously and has more predictable pharmacokinetics than unfractionated heparin.","oneSentence":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:58.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery or hip/knee replacement"},{"name":"Treatment of acute DVT and pulmonary embolism"},{"name":"Acute coronary syndrome (unstable angina and non-ST-segment elevation myocardial infarction)"},{"name":"Prevention of ischemic complications in patients with acute ST-segment elevation myocardial infarction"}]},"trialDetails":[{"nctId":"NCT03988231","phase":"PHASE4","title":"Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2021-07","conditions":"Venous Thromboembolism, Bleeding as Surgical Complication (Treatment), Deep Venous Thrombosis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Receipt of enoxaparin","genericName":"Receipt of enoxaparin","companyName":"University of Utah","companyId":"university-of-utah","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery or hip/knee replacement, Treatment of acute DVT and pulmonary embolism, Acute coronary syndrome (unstable angina and non-ST-segment elevation myocardial infarction).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}